SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-168545
Filing Date
2024-06-26
Accepted
2024-06-26 08:06:00
Documents
20
Period of Report
2024-06-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d822257d8k.htm   iXBRL 8-K 36652
2 EX-10.1 d822257dex101.htm EX-10.1 75644
3 EX-10.2 d822257dex102.htm EX-10.2 152018
4 EX-99.1 d822257dex991.htm EX-99.1 11147
8 GRAPHIC g822257dsp55.jpg GRAPHIC 3833
9 GRAPHIC g822257dsp69.jpg GRAPHIC 3899
10 GRAPHIC g822257g0625232539747.jpg GRAPHIC 3830
11 GRAPHIC g822257g28f43.jpg GRAPHIC 32878
  Complete submission text file 0001193125-24-168545.txt   522089

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ntla-20240621.xsd EX-101.SCH 2847
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20240621_lab.xml EX-101.LAB 17994
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20240621_pre.xml EX-101.PRE 11259
23 EXTRACTED XBRL INSTANCE DOCUMENT d822257d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 241070663
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)